Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-10-11
2009-08-25
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252180, C514S252190, C514S255050, C514S275000, C544S122000, C544S295000, C544S296000, C544S324000
Reexamination Certificate
active
07579349
ABSTRACT:
A compound of Formula (I); wherein the substituents are as defined in the text for use in modulating insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.
REFERENCES:
patent: 4038240 (1977-07-01), Hugl et al.
patent: 2426180 (1975-12-01), None
patent: 97/19065 (1997-05-01), None
patent: 00/12485 (2000-03-01), None
patent: 00/35455 (2000-06-01), None
patent: 00/39101 (2000-07-01), None
patent: 00/63182 (2000-10-01), None
patent: 01/22938 (2001-04-01), None
patent: 01/60816 (2001-08-01), None
patent: 01/64655 (2001-09-01), None
patent: 01/64656 (2001-09-01), None
patent: 01/85699 (2001-11-01), None
patent: 02/22601 (2002-03-01), None
patent: 02/22602 (2002-03-01), None
patent: 02/22603 (2002-03-01), None
patent: 02/22604 (2002-03-01), None
patent: 02/22605 (2002-03-01), None
patent: 02/22606 (2002-03-01), None
patent: 02/22607 (2002-03-01), None
patent: 02/22608 (2002-03-01), None
patent: 02/50065 (2002-06-01), None
patent: 03/048133 (2003-06-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
LeRoith et al., The insulin-like growth factor system and cancer, Cancer Letters, 195 (2003), pp. 127-137.
Breault, Gloria A., et al., “Cyclin-Dependent Kinase 4 Inhibitors as a Treatment for Cancer. Part 2: Identification and Optimisation of Substituted 2,4-Bis Anilino Pyrimidines”, Bioorganic & Medicinal Chemistry Letters, 2003, 2961-2966, vol. 13.
Pierce, Albert C. et al., “CH . . . O and CH . . . N Hydrogen Bonds in Ligand Design: A Novel Quinazolin-4-ylthiazol-2-ylamine Protein Kinase Inhibitor”, J. Med. Chem, 2005, 1278-1281, vol. 48.
Nowak Thorsten
Thomas Andrew Peter
AstraZeneca AB
Rao Deepak
LandOfFree
4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4099645